Fortrea Holdings

FTRE

Market cap $1.17B

DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December:

DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender Offer”) described in the Offer to Purchase dated October 20, 2025 by purchasing $75,743,000 in aggregate of the Company's outstanding 7.500% Senior Secured Notes due 2030 (CUSIP No. 34965K AA5 (Rule 144A); U31685 AA5 (Reg S)) (each, a “Note” and collectively, the “Notes”). The Tender Offer to repurchase of a portion of the Notes satisfied a requirement relating to the Company's divestiture of its Fortrea Patient Access and Endpoint Clinical businesses completed in June 2024. Fortrea's purchase of the tendered Notes on November 21, 2025, reduced the principal outstanding on the Notes from $570,000,000 to $494,257,000.

DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M.

DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately.

Fortrea Holdings Inc. ( FTRE ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tracy Krumme - Senior VP of Investor Relations Anshul Thakral - CEO & Director Jill McConnell - Chief Financial Officer Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division David Windley - Jefferies LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jenny Cao - Truist Securities, Inc., Research Division Alan Chen Presentation Operator Good day, and thank you for standing by.

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.23 per share a year ago.

For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 million GAAP net loss of $(15.9) million Adjusted EBITDA of $50.7 million GAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectively Book-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 months Cost saving initiatives remain on track Raising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to a range of $175 million to $195 million DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today reported financial results for the third quarter ended September 30, 2025.

DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session.

Amid U.S.-China tensions and the U.S. government shutdown, five high-earnings-yield value stocks stand out for long-term investors.

DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry.